Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application

- Rigorous humanized mouse model enhances credibility and translatability of results

- Key preclinical data to support FDA Orphan Drug Application

- In vitro success signals potential for exosome-based therapy breakthrough

ORLANDO, FL / ACCESS Newswire / April 29, 2025 /MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of cancer and other diseases, is pleased to announce the early completion of its preclinical trial for glioblastoma, a highly aggressive brain cancer. This milestone strengthens the company 's FDA Orphan Drug Application and positions Exousia Pro to become a leader in innovative cancer treatments.

Nearly 90% of glioblastoma preclinical studies rely on genetically engineered or chemically induced mouse models, limiting their relevance to human disease. Exousia Pro set a higher standard by employing a sophisticated humanized mouse model. By implanting surgically removed human glioblastoma tumor cells into immunodeficient mice, we ensured a clinically relevant evaluation of therapeutic efficacy. This approach significantly enhances the credibility of our results. While more costly, this rigorous approach ensures robust, translatable results, as the therapy 's efficacy is tested without interference from the mouse 's immune system.

The trial involved 32 mice implanted with glioblastoma patient-derived tumor cells into the brain. After a 14-day tumor establishment period, the mice were randomized into four cohorts: control, conventional temozolomide (TMZ) treatment alone, exosome treatment alone, and a TMZ-exosome combination therapy. Following seven days of treatment, evaluations focused on key metrics, including tumor size, and body weight changes to assess treatment efficacy and overall mouse health. Tumor size reduction will be critical in supporting the company 's FDA Orphan Drug Application, while detailed brain slices immunohistochemical analyses are expected to reveal the underlying therapeutic effects. A comprehensive report is expected by mid-to-late May 2025.

"This preclinical trial could alter the trajectory of exosomal-based therapies which has seen relatively low adoption due to production and manufacturing inefficiencies," said Mike Sheikh, CEO of Exousia Pro. "We can target and load the exosome in a singular process whereby the cell does all the work for us. Our in vitro studies demonstrated that our exosomal therapy, combined with minimal chemotherapy, significantly enhances the elimination of cancer stem cells-the primary barrier to effective glioblastoma therapy. If our preclinical results validate or exceed these findings, Exousia Pro could achieve global recognition and transform the standard of care for glioblastoma patients.

The company anticipates key positive preclinical data for submission to the FDA in order to advance the Orphan Drug Application, potentially unlocking significant regulatory and financial benefits.

About us

Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes via the targeted delivery of nuclear material. Initially the therapeutic focus will be on oncology, the company 's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The company 's proprietary loading technology can infuse a range of molecules from drugs to DNA.

For more information, please visit: www.exousiapro.com

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Exousia Pro 's forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Exousia Pro, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Marijuana, Inc.
www.Exousiapro.com
Twitter: @Exousia_Pro

Investor Relations
ir@exousiapro.com

SOURCE:Marijuana Inc.

View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire. All Rights Reserved.